Atreca
VerifiedPrecision Therapies from the Immune Response.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
($17m) (Public information from Jun 2024)
Share price
$0.09 BCEL
San Carlos California (HQ)
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 20 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (686 %) | (607 %) | (663 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (800 %) | (358 %) | (401 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | $0.0 | round |
| N/A | $0.0 | round | |
| investor investor investor investor | $0.0 | round | |
| investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| N/A | $0.0 Valuation: $0.0 -10.6x EV/LTM EBITDA | round | |
* | N/A | $125m | Post IPO Equity |
| Total Funding | 000k | ||
Related Content
Recent News about Atreca
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.